The DOI matches its Crossref record; 159 of the 159 references it cites were found in a registry or an index.
The diverse and complex roles of NF-κB subunits in cancer
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
4 retracted
Veuger, S. J., Hunter, J. E., & Durkacz, B. W. (2008) · Oncogene · doi:10.1038/onc.2008.439 · Cited by 135
RetractedRetracted: A cell cycle regulatory network controlling NF‐κB subunit activity and function
Barré, B., & Perkins, N. D. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601899 · Cited by 106
Self-citationRetractedBarré, B., & Perkins, N. D. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.03.018 · Cited by 72
Self-citationRetractedRegulation of activity and function of the p52 NF-κB subunit following DNA damage
Barré, B., Coqueret, O., & Perkins, N. D. (2010) · Cell Cycle · doi:10.4161/cc.9.24.14245 · Cited by 28
Self-citationRetractedHallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Immunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755
Chen, X., Xiu, M., Xing, J., Yu, S., Min, D., & Guo, F. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479439 · Cited by 5,742
Shared Principles in NF-κB Signaling
Hayden, M. S., & Ghosh, S. (2008) · Cell · doi:10.1016/j.cell.2008.01.020 · Cited by 4,494
Activators and target genes of Rel/NF-κB transcription factors
Pahl, H. L. (1999) · Oncogene · doi:10.1038/sj.onc.1203239 · Cited by 3,727
Nuclear factor-κB in cancer development and progression
Karin, M. (2006) · Nature · doi:10.1038/nature04870 · Cited by 3,519
Research works printed but not linked: 7
- Barre, B. & Perkins, N. D. Phosphorylation of the p52 NF-κB subunit. Cell cycle 9, 4774–4775 (2010). · doi:10.4161/cc.9.24.14246
- Rattan, R. et al. TCEAL7, a putative tumor suppressor gene, negatively regulates NF-κB pathway. Oncogene 29, 1362–1373 (2010). · doi:10.1038/onc.2009.431
- Bednarski, B. K., Baldwin, A. S. Jr & Kim, H. J. Addressing reported pro-apoptotic functions of NF-κB: targeted inhibition of canonical NF-κB enhances the apoptotic effects of doxorubicin. PLoS ONE 4, e6992 (2009). · doi:10.1371/journal.pone.0006992
- Campbell, K. J., O'Shea, J. M. & Perkins, N. D. Differential regulation of NF-κB activation and function by topoisomerase II inhibitors. BMC Cancer 6, 101 (2006). · doi:10.1186/1471-2407-6-101
- Manna, S. K., Manna, P. & Sarkar, A. Inhibition of RelA phosphorylation sensitizes apoptosis in constitutive NF-κB-expressing and chemoresistant cells. Cell Death Differ. 14, 158–170 (2007). · doi:10.1038/sj.cdd.4401929
- Roccaro, A. M., Vacca, A. & Ribatti, D. Bortezomib in the treatment of cancer. Recent Pat. Anticancer Drug Discov. 1, 397–403 (2006). · doi:10.2174/157489206778776925
- Trecca, D. et al. Identification of a tumor-associated mutant form of the NF- κB RelA gene with reduced DNA-binding and transactivating activities. Oncogene 14, 791–799 (1997). · doi:10.1038/sj.onc.1200895
Cited by
The complexity of NF-κB signaling in inflammation and cancer
Hoesel, B., & Schmid, J. A. (2013) · Molecular Cancer · doi:10.1186/1476-4598-12-86 · Cited by 3,165
NF-κB, inflammation, immunity and cancer: coming of age
Taniguchi, K., & Karin, M. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.142 · Cited by 2,679
Hayes, J. D., Dinkova-Kostova, A. T., & Tew, K. D. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.06.001 · Cited by 2,654
NF-κB in biology and targeted therapy: new insights and translational implications
Guo, Q., Jin, Y., Chen, X., Ye, X., Shen, X., Lin, M., Zeng, C., Zhou, T., & Zhang, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01757-9 · Cited by 2,047
30 Years of NF-κB: A Blossoming of Relevance to Human Pathobiology
Zhang, Q., Lenardo, M. J., & Baltimore, D. (2017) · Cell · doi:10.1016/j.cell.2016.12.012 · Cited by 1,982
Su, S., Chen, J., Yao, H., Liu, J., Yu, S., Lao, L., Wang, M., Luo, M., Xing, Y., Chen, F., et al. (2018) · Cell · doi:10.1016/j.cell.2018.01.009 · Cited by 1,230
Intestinal Tumorigenesis Initiated by Dedifferentiation and Acquisition of Stem-Cell-like Properties
Schwitalla, S., Fingerle, A. A., Cammareri, P., Nebelsiek, T., Göktuna, S. I., Ziegler, P. K., Canli, O., Heijmans, J., Huels, D. J., Moreaux, G., et al. (2013) · Cell · doi:10.1016/j.cell.2012.12.012 · Cited by 1,068
Mechanisms of chemoresistance in cancer stem cells
Abdullah, L. N., & Chow, E. K. (2013) · Clinical and Translational Medicine · doi:10.1186/2001-1326-2-3 · Cited by 721
Metabolic targets for cancer therapy
Galluzzi, L., Kepp, O., Heiden, M. G. V., & Kroemer, G. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4145 · Cited by 711
C11orf95–RELA fusions drive oncogenic NF-κB signalling in ependymoma
Parker, M., Mohankumar, K. M., Punchihewa, C., Weinlich, R., Dalton, J. D., Li, Y., Lee, R., Tatevossian, R. G., Phoenix, T. N., Thiruvenkatam, R., et al. (2014) · Nature · doi:10.1038/nature13109 · Cited by 670
Overcoming cancer therapeutic bottleneck by drug repurposing
Zhang, Z., Zhou, L., Xie, N., Nice, E. C., Zhang, T., Cui, Y., & Huang, C. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00213-8 · Cited by 516
The role of tumour-stromal interactions in modifying drug response: challenges and opportunities
McMillin, D. W., Negri, J. M., & Mitsiades, C. S. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3870 · Cited by 474
The nuclear factor kappa B signaling pathway: integrating metabolism with inflammation
Tornatore, L., Thotakura, A. K., Bennett, J., Moretti, M., & Franzoso, G. (2012) · Trends in Cell Biology · doi:10.1016/j.tcb.2012.08.001 · Cited by 447
Drug repurposing for cancer therapy
Xia, Y., Sun, M., Huang, H., & Jin, W.-L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01808-1 · Cited by 443
“139,140 hTERT-dependent transcription mediated through these pathways allows tumor cells to have unlimited replication capabilities.”
BackgroundChalcone Derivatives: Role in Anticancer Therapy
Ouyang, Y., Li, J., Chen, X., Fu, X., Sun, S., & Wu, Q. (2021) · Biomolecules · doi:10.3390/biom11060894 · Cited by 399
Telomerase directly regulates NF-κB-dependent transcription
Ghosh, A., Saginc, G., Leow, S. C., Khattar, E., Shin, E. M., Yan, T. D., Wong, M., Zhang, Z., Li, G., Sung, W.-K., et al. (2012) · Nature Cell Biology · doi:10.1038/ncb2621 · Cited by 378
NF‐κB and HIF crosstalk in immune responses
D'Ignazio, L., Bandarra, D., & Rocha, S. (2016) · The FEBS Journal · doi:10.1111/febs.13578 · Cited by 363
NFKB1: a suppressor of inflammation, ageing and cancer
Cartwright, T., Perkins, N. D., & L. Wilson, C. (2016) · The FEBS Journal · doi:10.1111/febs.13627 · Cited by 347
Self-citationNoncanonical NF-κB Signaling in Health and Disease
Cildir, G., Low, K. C., & Tergaonkar, V. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.03.002 · Cited by 301
Zerdes, I., Matikas, A., Bergh, J., Rassidakis, G. Z., & Foukakis, T. (2018) · Oncogene · doi:10.1038/s41388-018-0303-3 · Cited by 292
The biology of ergothioneine, an antioxidant nutraceutical
Borodina, I., Kenny, L. C., McCarthy, C. M., Paramasivan, K., Pretorius, E., Roberts, T. J., van der Hoek, S. A., & Kell, D. B. (2020) · Nutrition Research Reviews · doi:10.1017/s0954422419000301 · Cited by 296
Freudlsperger, C., Bian, Y., Contag Wise, S., Burnett, J., Coupar, J., Yang, X., Chen, Z., & Van Waes, C. (2013) · Oncogene · doi:10.1038/onc.2012.171 · Cited by 290
Targeting the Tumor Microenvironment: From Understanding Pathways to Effective Clinical Trials
Fang, H., & DeClerck, Y. A. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0661 · Cited by 284
Targeting the NFκB Signaling Pathways for Breast Cancer Prevention and Therapy
Wang, W., Nag, S., & Zhang, R. (2014) · Current Medicinal Chemistry · doi:10.2174/0929867321666141106124315 · Cited by 282
Targeting the PI3K/Akt/mTOR Pathway in Hepatocellular Carcinoma
Sun, E. J., Wankell, M., Palamuthusingam, P., McFarlane, C., & Hebbard, L. (2021) · Biomedicines · doi:10.3390/biomedicines9111639 · Cited by 281
Anti‐tumour strategies aiming to target tumour‐associated macrophages
Tang, X., Mo, C., Wang, Y., Wei, D., & Xiao, H. (2013) · Immunology · doi:10.1111/imm.12023 · Cited by 278
Non-canonical NF-κB Antagonizes STING Sensor-Mediated DNA Sensing in Radiotherapy
Hou, Y., Liang, H., Rao, E., Zheng, W., Huang, X., Deng, L., Zhang, Y., Yu, X., Xu, M., Mauceri, H., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.07.008 · Cited by 265
O-GlcNAcylation: A New Cancer Hallmark?
Fardini, Y., Dehennaut, V., Lefebvre, T., & Issad, T. (2013) · Frontiers in Endocrinology · doi:10.3389/fendo.2013.00099 · Cited by 263
Brd4 maintains constitutively active NF-κB in cancer cells by binding to acetylated RelA
Zou, Z., Huang, B., Wu, X., Zhang, H., Qi, J., Bradner, J., Nair, S., & Chen, L.-F. (2014) · Oncogene · doi:10.1038/onc.2013.179 · Cited by 259
Tigan, A.-S., Bellutti, F., Kollmann, K., Tebb, G., & Sexl, V (2016) · Oncogene · doi:10.1038/onc.2015.407 · Cited by 204
Blakely, C. M., Pazarentzos, E., Olivas, V., Asthana, S., Yan, J. J., Tan, I., Hrustanovic, G., Chan, E., Lin, L., Neel, D. S., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.03.012 · Cited by 204
Cancer Chemoprevention and Nutri-Epigenetics: State of the Art and Future Challenges
Gerhauser, C. (2012) · Topics in Current Chemistry · doi:10.1007/128_2012_360 · Cited by 194
An integrative ENCODE resource for cancer genomics
Zhang, J., Lee, D., Dhiman, V., Jiang, P., Xu, J., McGillivray, P., Yang, H., Liu, J., Meyerson, W., Clarke, D., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14743-w · Cited by 172
Endothelial-cell FAK targeting sensitizes tumours to DNA-damaging therapy
Tavora, B., Reynolds, L. E., Batista, S., Demircioglu, F., Fernandez, I., Lechertier, T., Lees, D. M., Wong, P.-P., Alexopoulou, A., Elia, G., et al. (2014) · Nature · doi:10.1038/nature13541 · Cited by 163
Self-citationNF-κB: a double-edged sword controlling inflammation
Liu, D., Zhong, Z., & Karin, M. (2022) · Biomedicines · doi:10.3390/biomedicines10061250 · Cited by 157
Cell Senescence, DNA Damage, and Metabolism
Shmulevich, R., & Krizhanovsky, V. (2021) · Antioxidants & Redox Signaling · doi:10.1089/ars.2020.8043 · Cited by 157
Cyclin-Dependent Kinase 6 Is a Chromatin-Bound Cofactor for NF-κB-Dependent Gene Expression
Handschick, K., Beuerlein, K., Jurida, L., Bartkuhn, M., Müller, H., Soelch, J., Weber, A., Dittrich-Breiholz, O., Schneider, H., Scharfe, M., et al. (2014) · Molecular Cell · doi:10.1016/j.molcel.2013.12.002 · Cited by 141
Kondylis, V., Polykratis, A., Ehlken, H., Ochoa-Callejero, L., Straub, B. K., Krishna-Subramanian, S., Van, T.-M., Curth, H.-M., Heise, N., Weih, F., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.10.001 · Cited by 131
KPC1-Mediated Ubiquitination and Proteasomal Processing of NF-κB1 p105 to p50 Restricts Tumor Growth
Kravtsova-Ivantsiv, Y., Shomer, I., Cohen-Kaplan, V., Snijder, B., Superti-Furga, G., Gonen, H., Sommer, T., Ziv, T., Admon, A., Naroditsky, I., et al. (2015) · Cell · doi:10.1016/j.cell.2015.03.001 · Cited by 117
Proteomic screen reveals Fbw7 as a modulator of the NF-κB pathway
Arabi, A., Ullah, K., Branca, R. M. M., Johansson, J., Bandarra, D., Haneklaus, M., Fu, J., Ariës, I., Nilsson, P., Den Boer, M. L., et al. (2012) · Nature Communications · doi:10.1038/ncomms1975 · Cited by 90
Huang, X., Yao, Y., Hou, X., Wei, L., Rao, Y., Su, Y., Zheng, G., Ruan, X. Z., Li, D., & Chen, Y. (2022) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2022.03.006 · Cited by 70
The Activation of IL-1-Induced Enhancers Depends on TAK1 Kinase Activity and NF-κB p65
Jurida, L., Soelch, J., Bartkuhn, M., Handschick, K., Müller, H., Newel, D., Weber, A., Dittrich-Breiholz, O., Schneider, H., Bhuju, S., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.01.001 · Cited by 51
Song, L., Zhu, S., Liu, C., Zhang, Q., & Liang, X. (2022) · Journal of Food Biochemistry · doi:10.1111/jfbc.13703 · Cited by 51
Breuer, R., Becker, M. S., Brechmann, M., Mock, T., Arnold, R., & Krammer, P. H. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.533547 · Cited by 40
Phylogenetic Analysis Supports a Link between DUF1220 Domain Number and Primate Brain Expansion
Zimmer, F., & Montgomery, S. H. (2015) · Genome Biology and Evolution · doi:10.1093/gbe/evv122 · Cited by 36
RhoA GTPase oxidation stimulates cell proliferation via nuclear factor-κB activation
Kim, J.-G., Kwon, H.-J., Wu, G., Park, Y., Lee, J.-Y., Kim, J., Kim, S.-C., Choe, M., Kang, S. G., Seo, G.-Y., et al. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.12.013 · Cited by 31
Tyr42 phosphorylation of RhoA GTPase promotes tumorigenesis through nuclear factor (NF)-κB
Kim, J.-G., Choi, K.-C., Hong, C.-W., Park, H.-S., Choi, E.-K., Kim, Y.-S., & Park, J.-B. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.07.013 · Cited by 28
Liu, T. W., Gammon, S. T., Yang, P., Fuentes, D., & Piwnica-Worms, D. (2021) · Science Signaling · doi:10.1126/scisignal.aax5971 · Cited by 27
WANG, J., YI, S., ZHOU, J., ZHANG, Y., & GUO, F. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3500 · Cited by 25
Ablation of miR-146b in mice causes hematopoietic malignancy
Mitsumura, T., Ito, Y., Chiba, T., Matsushima, T., Kurimoto, R., Tanaka, Y., Kato, T., Uchida, K., Ito, T., Yamamoto, K., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018017954 · Cited by 22
Mutually exclusive roles of SHARPIN in integrin inactivation and NF-κB signaling
De Franceschi, N., Peuhu, E., Parsons, M., Rissanen, S., Vattulainen, I., Salmi, M., Ivaska, J., & Pouwels, J. (2015) · PLOS ONE · doi:10.1371/journal.pone.0143423 · Cited by 22
Liu, T. W., Gammon, S. T., Fuentes, D., & Piwnica-Worms, D. (2021) · Cells · doi:10.3390/cells10030489 · Cited by 16
Konrath, F., Willenbrock, M., Busse, D., Scheidereit, C., & Wolf, J. (2023) · iScience · doi:10.1016/j.isci.2023.107917 · Cited by 7
Metadata
- Authors
- Perkins, N. D.
- Venue
- Nature Reviews Cancer
- Published
- 2012-01-19
- Volume
- 12
- Issue
- 2
- Pages
- 121-132
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2042073539
- Cited by
- 852
- References
- 159
- FWCI
- 4.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.